Aquestive Therapeutics Inc (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercialising differentiated products to solve therapeutic problems, announced yesterday that it has named Daniel Barber as its new senior vice president, chief operating officer effective 6 May 2019.
Barber has worked at Aquestive since 2007, most recently in the role of senior vice president, chief strategy and development officer. A twelve-year veteran of Aquestive, Barber held a series of positions of increasing responsibility with the company including finance director, senior director of Alliance Management, and vice president of Business Development. Prior to his tenure at Aquestive, he served in roles at Xerox and Quest Diagnostics.
Keith J Kendall, Aquestive Therapeutics' chief executive officer, said, 'Dan has been a member of the Aquestive team for over a decade and has been integral in helping the Company to evolve into a publicly-traded, specialty pharmaceutical company with a strong developmental pipeline, marketed products, and in-house manufacturing. As our Company continues to grow, Dan's broad skillset will ensure our strategies, capabilities, and operations adapt in line with organizational and market needs.'
Convergent Therapeutics names new chairman of board of directors
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Cardinal Health names new independent director
Micron Biomedical names new scientific advisor to CEO
MedPharm names new executive chairman
Armonica Technologies names new director
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Ardigen names new chief commercial officer
AbbVie names new chief executive officer
AMO Pharma collaborates with Population Health Research Institute for tideglusib clinical trial